The high profile and relatively new manufacturer, Moderna Inc has announced today an expansion of their existin Biomedical Advanced Research and Development Authority (BARDA) agreement.

The agreement will expand funding by up to $472 million in part to support the Phase 3 study of mRNA-1273, the company's COVID-19 vaccine. This funding expands on Moderna's previous agreement with BARDA for $483 million.

“We thank BARDA for this continued commitment to mRNA-1273, our vaccine candidate against COVID-19.” said Stéphane Bancel, Moderna’s Chief Executive Officer. “Encouraged by the Phase 1 data, we believe that our mRNA vaccine may aid in addressing the COVID-19 pandemic and preventing future outbreaks.”

BARDA is a part of the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services. Moderna is among a short list of COVID-19 vaccine manufacturers as part of  an agreement made with the U.S. Department of Health and Human Services and the Department of Defense. The initiative is part of the Trump administration's "Operation Warp Speed" (OWS). OWS's goal is to deliver 300 million doses of COVID-19 vaccines in 2021.

Moderna expects to produce 500 million doses of mRNA-1273 per year, and possibly up to 1 billion doses per year, beginning in 2021.